Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: EST002
MIFTS: 46

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

About this section

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060076
Sources

Summaries for Estrogen-Receptor Negative Breast Cancer

About this section
Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to estrogen-receptor positive breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are PAK Pathway and Gastric cancer. The drugs Bevacizumab and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Estrogen-Receptor Negative Breast Cancer

About this section

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 30.7 ERBB2 ESR1 PGR
2 breast cancer 29.9 AHR AR CXCL8 EGF ERBB2 ESR1
3 vestibular gland benign neoplasm 10.4 ESR1 PGR
4 bartholin's gland adenoma 10.4 ESR1 PGR
5 vulvar syringoma 10.4 ESR1 PGR
6 scirrhous adenocarcinoma 10.4 ERBB2 PGR
7 lung leiomyoma 10.4 ESR1 PGR
8 breast apocrine carcinoma 10.4 ERBB2 PGR
9 vulvar benign neoplasm 10.4 ESR1 PGR
10 trigonitis 10.4 ESR1 PGR
11 vulvar leiomyoma 10.4 ESR1 PGR
12 comedo carcinoma 10.4 ERBB2 ESR1
13 predominantly cortical thymoma 10.4 ESR1 PGR
14 intracystic papillary adenoma 10.4 ERBB2 PGR
15 breast metaplastic carcinoma 10.4 ERBB2 PGR
16 postmenopausal atrophic vaginitis 10.4 AR ESR1
17 progesterone-receptor negative breast cancer 10.4 ERBB2 PGR
18 bartholin's gland benign neoplasm 10.4 ESR1 PGR
19 progesterone resistance 10.4 ESR1 PGR
20 cribriform carcinoma 10.4 ESR1 PGR
21 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
22 adenoid basal cell carcinoma 10.4 ESR1 PGR
23 deep angioma 10.4 ESR1 PGR
24 synchronous bilateral breast carcinoma 10.4 ESR1 PGR
25 uterine body mixed cancer 10.3 ERBB2 PGR
26 female reproductive endometrioid cancer 10.3 ESR1 PGR
27 corneal abscess 10.3 AR PGR
28 cervical carcinosarcoma 10.3 ESR1 PGR
29 estrogen excess 10.3 ESR1 PGR
30 sebaceous adenoma 10.3 EGF ESR1
31 bartholin's gland disease 10.3 AR PGR
32 intramuscular hemangioma 10.3 ESR1 PGR
33 calcifying aponeurotic fibroma 10.3 EGF PGR
34 glycogen-rich clear cell breast carcinoma 10.3 ESR1 PGR
35 mammographic density 10.3 ESR1 PGR
36 cervical clear cell adenocarcinoma 10.3 ESR1 PGR
37 glassy cell carcinoma of the cervix 10.3 ERBB2 ESR1 PGR
38 breast medullary carcinoma 10.3 ERBB2 ESR1 PGR
39 breast scirrhous carcinoma 10.3 ERBB2 ESR1 PGR
40 progesterone-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
41 microglandular adenosis 10.3 ERBB2 PGR
42 retinitis pigmentosa 47 10.3 ESR1 PGR
43 inflammatory breast carcinoma 10.3 ERBB2 ESR1 PGR
44 luminal breast carcinoma 10.3 ERBB2 ESR1 PGR
45 breast benign neoplasm 10.3 ERBB2 ESR1 PGR
46 oncocytic breast carcinoma 10.3 AR ESR1 PGR
47 thoracic benign neoplasm 10.3 ERBB2 ESR1 PGR
48 uterine corpus cancer 10.3 ERBB2 ESR1 PGR
49 endometrial squamous cell carcinoma 10.3 AR ESR1 PGR
50 lipid-rich carcinoma 10.3 ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer
Sources

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

About this section

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 AHR AR CCAR2 ERBB2 ESR1 NOS2
2 cellular MP:0005384 10.19 AHR AR ERBB2 ESR1 NOS2 PGR
3 growth/size/body region MP:0005378 10.19 AHR AR CCAR2 EGF ERBB2 ESR1
4 homeostasis/metabolism MP:0005376 10.18 AHR AR CCAR2 ERBB2 ESR1 NOS2
5 endocrine/exocrine gland MP:0005379 10.16 AHR AR EGF ERBB2 ESR1 NOS2
6 cardiovascular system MP:0005385 10.15 AHR AR ERBB2 ESR1 NOS2 PGR
7 digestive/alimentary MP:0005381 10.13 AHR AR EGF ERBB2 ESR1 NOS2
8 immune system MP:0005387 10.11 AHR AR CCAR2 EGF ESR1 NOS2
9 integument MP:0010771 9.98 AHR AR EGF ERBB2 ESR1 NOS2
10 muscle MP:0005369 9.97 AHR AR ERBB2 ESR1 NOS2 PGR
11 liver/biliary system MP:0005370 9.95 AHR AR CCAR2 ESR1 NOS2 TGFBR2
12 neoplasm MP:0002006 9.92 AHR AR CCAR2 ERBB2 ESR1 NOS2
13 normal MP:0002873 9.8 AR EGF ERBB2 ESR1 PGR TGFBR2
14 reproductive system MP:0005389 9.76 AHR AR EGF ERBB2 ESR1 NOS2
15 respiratory system MP:0005388 9.43 AHR ERBB2 ESR1 NOS2 TGFBR2 WNT5A
16 skeleton MP:0005390 9.23 AHR AR ERBB2 ESR1 NOS2 PGR
Sources

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

About this section

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
2
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
6
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
7
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 38904 10339178 498142
9
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
11
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
12
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
13
Goserelin Approved Phase 3 65807-02-5 5311128 47725
14
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
15
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
19
Doxil Approved June 1999 Phase 3,Phase 2 31703
20
Lapatinib Approved March 2007, Investigational Phase 3 388082-78-8, 231277-92-2 208908 9941095
21 Angiogenesis Inhibitors Phase 3,Phase 2,Not Applicable
22 Angiogenesis Modulating Agents Phase 3,Phase 2,Not Applicable
23 Anti-Bacterial Agents Phase 3,Phase 2
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimetabolites Phase 3,Phase 2
26 Antineoplastic Agents, Immunological Phase 3,Phase 2,Not Applicable
27 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
29 Antimetabolites, Antineoplastic Phase 3,Phase 2
30 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
31 Immunologic Factors Phase 3,Phase 2,Not Applicable
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antibiotics, Antitubercular Phase 3,Phase 2
35 Progestins Phase 3,Phase 2,Phase 1,Not Applicable
36 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
37 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
40 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3
41 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 2, Phase 3
43 Antiviral Agents Phase 2, Phase 3
44 Triamcinolone hexacetonide Phase 3
45 Triamcinolone diacetate Phase 3
46 triamcinolone acetonide Phase 3
47 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
48 Antineoplastic Agents, Hormonal Phase 3,Phase 2
49 Folic Acid Antagonists Phase 3,Phase 2
50 Dermatologic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel;Carboplatin;Gemcitabine
3 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
4 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
5 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
6 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
7 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
8 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
9 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
10 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
11 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
12 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Active, not recruiting NCT01471106 Phase 2 Dasatinib
13 Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer Completed NCT00239343 Phase 2 gefitinib
14 GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
15 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
16 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Completed NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
17 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
18 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Active, not recruiting NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
19 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
20 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
21 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Terminated NCT01234532 Phase 2 entinostat;anastrozole
22 RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Terminated NCT01217411 Phase 1, Phase 2 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
23 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
24 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Completed NCT00559507 Phase 2 saracatinib
25 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
26 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
27 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
28 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
29 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2 PD-0332991
30 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
31 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
32 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
33 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
34 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
35 Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
36 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
37 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
38 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
39 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
40 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
41 Study of Tumor and Blood Samples From Women With Breast Cancer Unknown status NCT00897728
42 Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer Terminated NCT00503841 Not Applicable erlotinib hydrochloride
43 Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer Completed NCT00900133
44 Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer Completed NCT00870168 Not Applicable chemotherapy
45 Evaluating the Relative Effectiveness of Two Front-of-pack Nutrition Labels Completed NCT03761342 Not Applicable
46 TC Avastin. ICORG 08-10, V6 Completed NCT00911716 Not Applicable cyclophosphamide;docetaxel
47 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892
48 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
49 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293 Not Applicable
50 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

About this section
Sources

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

About this section

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

42
Breast, Brain, Lymph Node, Bone, T Cells, Colon, Prostate
Sources

Publications for Estrogen-Receptor Negative Breast Cancer

About this section

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 178)
# Title Authors Year
1
Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. ( 30617282 )
2019
2
Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. ( 29518546 )
2018
3
Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. ( 29378048 )
2018
4
Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. ( 30260018 )
2018
5
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. ( 29141994 )
2017
6
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. ( 28238761 )
2017
7
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. ( 29058716 )
2017
8
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )
2017
9
WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. ( 28469783 )
2017
10
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. ( 29087320 )
2017
11
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. ( 28881566 )
2017
12
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. ( 28280355 )
2017
13
Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. ( 28957356 )
2017
14
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit I^-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. ( 29069648 )
2017
15
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )
2017
16
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. ( 28877935 )
2017
17
Effect of 17I^-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. ( 29133279 )
2017
18
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )
2016
19
Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )
2016
20
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )
2016
21
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )
2016
22
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )
2016
23
Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )
2016
24
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )
2016
25
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )
2016
26
Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )
2016
27
The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )
2016
28
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )
2016
29
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". ( 26874356 )
2016
30
Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )
2015
31
NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )
2015
32
Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )
2015
33
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )
2015
34
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )
2015
35
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )
2015
36
Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )
2015
37
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )
2015
38
Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )
2015
39
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )
2015
40
Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )
2015
41
Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )
2015
42
In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )
2014
43
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )
2014
44
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )
2014
45
Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )
2014
46
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )
2014
47
A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )
2014
48
Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )
2014
49
Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )
2014
50
The prevalence of estrogen receptor-negative breast cancer in Ethiopia. ( 25433805 )
2014
Sources

Variations for Estrogen-Receptor Negative Breast Cancer

About this section
Sources

Expression for Estrogen-Receptor Negative Breast Cancer

About this section
Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.
Sources

Pathways for Estrogen-Receptor Negative Breast Cancer

About this section

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
PAK Pathway 65
Show member pathways
 13.04 CXCL8 CYB5R3 EGF ERBB2 PTPRA TGFBR2
2
Gastric cancer 38
Show member pathways
 12.3 EGF ERBB2 ESR1 PGR TGFBR2 WNT5A
3
Pathways in cancer 38
11.95 AR CXCL8 EGF ERBB2 ESR1 NOS2
4
Colorectal Cancer Metastasis 65
11.92 EGF NOS2 TGFBR2 WNT5A
5
Integrated Breast Cancer Pathway 1
11.86 AHR AR ESR1 TGFBR2
6
Spinal Cord Injury 1
11.79 CXCL8 NOS2 PTPRA
7
HIF-1 signaling pathway 38
11.69 EGF ERBB2 NOS2
8
TGF-beta Signaling Pathways 66
11.64 AR ESR1 TGFBR2
9
Nuclear Receptor transcription pathway 67
Show member pathways
 11.59 AR ESR1 PGR
10
Signaling by ERBB4 67
Show member pathways
 11.59 EGF ERBB2 ESR1 PGR
11
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 11.52 AR EGF ERBB2 TGFBR2 WNT5A
12
Bladder cancer 38 1
11.47 CXCL8 EGF ERBB2
13
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.39 EGF ERBB2 TGFBR2
14
Extracellular vesicle-mediated signaling in recipient cells 1
10.97 ERBB2 TGFBR2 WNT5A
15
AHR Pathway 65
10.95 AHR ESR1
Sources

GO Terms for Estrogen-Receptor Negative Breast Cancer

About this section

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.92 EGF ERBB2 PTPRA TGFBR2

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.87 AR EGF ERBB2 WNT5A
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 AHR AR EGF ESR1 WNT5A
3 positive regulation of protein kinase B signaling GO:0051897 9.77 EGF ERBB2 ESR1
4 cellular response to lipopolysaccharide GO:0071222 9.76 CXCL8 NOS2 WNT5A
5 positive regulation of angiogenesis GO:0045766 9.73 CXCL8 TGFBR2 WNT5A
6 phosphatidylinositol phosphorylation GO:0046854 9.71 EGF ERBB2 ESR1
7 male gonad development GO:0008584 9.69 AR ESR1 WNT5A
8 wound healing GO:0042060 9.67 ERBB2 TGFBR2 WNT5A
9 positive regulation of mesenchymal cell proliferation GO:0002053 9.58 TGFBR2 WNT5A
10 uterus development GO:0060065 9.55 ESR1 WNT5A
11 steroid hormone mediated signaling pathway GO:0043401 9.54 AR ESR1 PGR
12 secondary palate development GO:0062009 9.52 TGFBR2 WNT5A
13 vagina development GO:0060068 9.43 ESR1 WNT5A
14 intracellular receptor signaling pathway GO:0030522 9.43 AHR AR ESR1
15 negative regulation of ERBB signaling pathway GO:1901185 9.4 EGF ERBB2
16 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.32 ESR1 WNT5A
17 positive regulation of transcription by RNA polymerase III GO:0045945 9.18 AR
18 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.16 AR PGR
19 lateral sprouting involved in mammary gland duct morphogenesis GO:0060599 8.96 AR WNT5A
20 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.89 AHR AR ESR1 PGR WNT5A
2 enzyme binding GO:0019899 9.73 AR CCAR2 ESR1 PGR
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGF ERBB2 PTPRA
4 ATPase binding GO:0051117 9.5 AR ESR1 PGR
5 TBP-class protein binding GO:0017025 9.48 AHR ESR1
6 transcription coactivator binding GO:0001223 9.46 AHR ESR1
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGF ERBB2 ESR1
8 steroid hormone receptor activity GO:0003707 9.33 AR ESR1 PGR
9 steroid binding GO:0005496 9.13 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 8.92 AHR AR ESR1 PGR
11 protein binding GO:0005515 10.18 AHR AR CCAR2 CXCL8 CYB5R3 EGF
Sources

Sources for Estrogen-Receptor Negative Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....